cenerimod
Sponsor Viatris INC · listed as VTRS
cenerimod is a drug asset sponsored by Viatris INC, listed as VTRS. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Dec 31, 2026 (day precision, medium confidence), tied to trial NCT05672576. That trial is in Phase 3 and currently active not recruiting, studying Lupus Erythematosus, Systemic. It appears across 4 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
All tracked catalysts for cenerimod
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2026-12-31 | READOUT | medium | NCT05672576 |
| 2027-03-31 | READOUT | medium | NCT05648500 |
Trials for cenerimod in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT05672576 catalyst | Phase 3 | Active, not recruiting | 2026-12-31 | Experimental | Viatris Innovation GmbH | Lupus Erythematosus, Systemic |
| NCT05648500 catalyst | Phase 3 | Active, not recruiting | 2027-03-31 | Experimental | Viatris Innovation GmbH | Lupus Erythematosus, Systemic |
| NCT07201129 | Phase 3 | Recruiting | 2029-08 | Experimental | Viatris Innovation GmbH | Nephritis, Lupus; Lupus Erythematosus, Systemic |
| NCT06475742 | Phase 3 | Enrolling by invitation | 2032-09 | Experimental | Viatris Innovation GmbH | Lupus Erythematosus, Systemic |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More VTRS catalysts